Evidence map›Paper›PMID 32077982›Full record

ReviewHerz2020

[Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Matthias Totzeck, Tienush Rassaf

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthias TotzeckKlinik für Kardiologie und Angiologie, Westdeutsches Herz- und Gefäßzentrum Essen, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland. matthias.totzeck@uk-essen.de.
Tienush RassafKlinik für Kardiologie und Angiologie, Westdeutsches Herz- und Gefäßzentrum Essen, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiotoxic side effects can significantly limit the quality of life and survival of tumor patients under treatment. Acute and chronic effects include hypertension, venous and arterial thromboembolic events, acute and chronic coronary syndromes, heart failure and arrhythmias. Patients with previous cardiovascular diseases are often more frequently affected by side effects. The triggers are not only irradiation and conventional chemotherapy but increasingly also newer forms of cancer treatment. These include targeted therapy and immune checkpoint inhibitors (ICI). The goals of oncological cardiology are the prevention, timely diagnosis and treatment of these side effects in order to optimize patient outcomes.

Indexed as

Antineoplastic AgentsCardiovascular DiseasesNeoplasmsCardiologistsHumansQuality of LifeRisk FactorsAntineoplastic AgentsCardiovascular diseasesImmune checkpoint therapyOncological cardiologySide effectsTargeted therapies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.